| Autor: |
Mahrukh A, Huseni, Lifen, Wang, Joanna E, Klementowicz, Kobe, Yuen, Beatrice, Breart, Christine, Orr, Li-Fen, Liu, Yijin, Li, Vinita, Gupta, Congfen, Li, Deepali, Rishipathak, Jing, Peng, Yasin, Şenbabaoǧlu, Zora, Modrusan, Shilpa, Keerthivasan, Shravan, Madireddi, Ying-Jiun, Chen, Eleanor J, Fraser, Ning, Leng, Habib, Hamidi, Hartmut, Koeppen, James, Ziai, Kenji, Hashimoto, Marcella, Fassò, Patrick, Williams, David F, McDermott, Jonathan E, Rosenberg, Thomas, Powles, Leisha A, Emens, Priti S, Hegde, Ira, Mellman, Shannon J, Turley, Mark S, Wilson, Sanjeev, Mariathasan, Luciana, Molinero, Mark, Merchant, Nathaniel R, West |
| Rok vydání: |
2022 |
| Zdroj: |
Cell reports. Medicine. |
| ISSN: |
2666-3791 |
| Popis: |
Although immune checkpoint inhibitors (ICIs) are established as effective cancer therapies, overcoming therapeutic resistance remains a critical challenge. Here we identify interleukin 6 (IL-6) as a correlate of poor response to atezolizumab (anti-PD-L1) in large clinical trials of advanced kidney, breast, and bladder cancers. In pre-clinical models, combined blockade of PD-L1 and the IL-6 receptor (IL6R) causes synergistic regression of large established tumors and substantially improves anti-tumor CD8 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
